ACSNCT07102628
Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Trial sites reduced: 69 → 65 locations
- Enrollment target: estimated 300 to confirmed 305
- Primary and study completion dates: Feb 11, 2027 to Jan 16, 2027
- Notable Eligibility criteria expanded, about 71 words
- Secondary endpoints: details revised at 4 of 10 entries
- Study description expanded, about 5 words
- Minor Study sites: 68 to 69v11
- Minor Trial sites expanded: 63 → 68 locationsv10
- Minor Trial sites expanded: 60 → 63 locationsv9
- Minor Study sites: 58 to 60v8
- Minor Trial sites expanded: 52 → 58 locations
- Primary and study completion dates: Feb 15, 2027 to Feb 11, 2027
- Minor Trial sites expanded: 26 → 52 locationsv6
- Minor Study sites: 15 to 26v5
- Minor Study sites: 9 to 15v4
- Minor Study sites: 2 to 9v3
- Notable Trial status: Not Yet Recruiting to Recruiting
- Study sites: 0 to 2
- Primary and study completion dates: Mar 6, 2027 to Feb 15, 2027
- Start date changed from estimate of Sep 30, 2025 to Oct 3, 2025
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (10)
Show 5 moreShow less
Arms and interventions
* Inclisiran sodium 300 mg subcutaneous (s.c.) on top of HIS (+/- LLT) or non-statin LLT in statin intolerant participants * KJX839 284 mg / 1.5 mL (Dose: 300 mg) * Pharmaceutical Dosage Form: solution for subcutaneous injection
* Matching placebo on top of HIS (+/- LLT) or non-statin LLT in statin intolerant participants * KJX839 Placebo / 1.5 mL (Dose: 0 mg) * Pharmaceutical Dosage Form: solution for subcutaneous injection
Drugs: Placebo, Inclisiran
Sites
65 sites in 13 countries
China 15, Spain 9, Germany 6, France 5, Hungary 5, Canada 4, India 4, Japan 4, Poland 4, Switzerland 3, Australia 2, Hong Kong 2, South Korea 2